SC
NBIX icon

SummitTX Capital’s Neurocrine Biosciences NBIX Stock Holding History

SummitTX Capital’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,777
Closed -$249K – 883
2025
Q3 		$249K Buy
+1,777
New +$241K 0.01% 666

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

SummitTX Capital's NBIX Position: Q4 2025 in Review

SummitTX Capital sold out of Neurocrine Biosciences (NBIX) in Q4 2025, closing a stake of 1,777 shares — an estimated $249K sold.

SummitTX Capital first reported a position in NBIX in Q3 2025 and held it in 1 quarter. The position peaked at $249K in Q3 2025. 733 funds tracked by Wall St. Rank hold NBIX as of Q4 2025.

  • SummitTX Capital reported no remaining Neurocrine Biosciences position as of Q4 2025 after selling out during the quarter.
  • SummitTX Capital sold 1,777 Neurocrine Biosciences shares in Q4 2025, an estimated $249K.
  • SummitTX Capital first reported a position in Neurocrine Biosciences in Q3 2025 and held it in 1 quarter.
  • SummitTX Capital's Neurocrine Biosciences position peaked at $249K in Q3 2025.
  • 733 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2025.

Based on SummitTX Capital's 13F filing for Q4 2025, filed 17 Feb 2026.